Pancreatic Safety of Incretin-Based Drugs - FDA and EMA Assessment.

The article discusses the comprehensive evaluations undertaken by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on the safety of incretin-based drugs on patients with pancreatitis or pancreatic cancer. Topics discussed include a description of the drug incretin, the FDA's study with the drug exenatide on rats with diabetes, and results of two cardiovascular outcome trials. A list of approved incretin-based drugs by FDA and EMA is also provided.